I-Mab (IMAB) - Total Liabilities
Based on the latest financial reports, I-Mab (IMAB) has total liabilities worth $18.50 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
I-Mab - Total Liabilities Trend (2017–2024)
This chart illustrates how I-Mab's total liabilities have evolved over time, based on quarterly financial data. See how liquid is I-Mab's working capital to evaluate short-term liquidity relative to the company's equity base.
I-Mab Competitors by Total Liabilities
The table below lists competitors of I-Mab ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jinfa Labi Maternity & Baby Articles Co Ltd
SHE:002762
|
China | CN¥146.19 Million |
|
Xiamen Savings Environmental
SHE:300056
|
China | CN¥645.90 Million |
|
Jiangsu Skyray Instrument Co
SHE:300165
|
China | CN¥2.02 Billion |
|
Eastern & Oriental Bhd
KLSE:3417
|
Malaysia | RM2.55 Billion |
|
UE Furniture Co Ltd
SHG:603600
|
China | CN¥2.28 Billion |
|
Shanghai Conglin Environmental Protection Technology Co. Ltd. A
SHG:688370
|
China | CN¥479.28 Million |
|
Rongfeng Holding Group
SHE:000668
|
China | CN¥450.66 Million |
|
Fenerbahce Futbol AS
IS:FENER
|
Turkey | TL19.22 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down I-Mab's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see I-Mab (IMAB) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how I-Mab's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for I-Mab (2017–2024)
The table below shows the annual total liabilities of I-Mab from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.52 Million | -98.71% |
| 2023-12-31 | $894.81 Million | -16.01% |
| 2022-12-31 | $1.07 Billion | +2.28% |
| 2021-12-31 | $1.04 Billion | +47.41% |
| 2020-12-31 | $706.65 Million | -81.27% |
| 2019-12-31 | $3.77 Billion | +13.25% |
| 2018-12-31 | $3.33 Billion | +151.37% |
| 2017-12-31 | $1.33 Billion | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more